AI Engines For more Details: Perplexity Kagi Labs You
Antihistamine Effects: Diphenhydramine hydrochloride blocks the action of histamine, a substance in the body involved in allergic reactions. This action helps alleviate symptoms such as itching, sneezing, runny nose, and watery eyes associated with allergies.
Sedative Effects: Diphenhydramine hydrochloride is known for its sedative properties, which can induce drowsiness and promote sleep. It is often included in over-the-counter sleep aids for its ability to help individuals fall asleep.
Anticholinergic Effects: Diphenhydramine hydrochloride also has anticholinergic properties, meaning it blocks the action of acetylcholine, a neurotransmitter in the brain. This can lead to side effects such as dry mouth, blurred vision, constipation, urinary retention, and confusion, particularly in older adults.
Cognitive Impairment: The anticholinergic effects of diphenhydramine hydrochloride can potentially cause cognitive impairment, especially in older adults. Long-term or high-dose use of anticholinergic medications has been associated with an increased risk of cognitive decline, dementia, and delirium. Therefore, caution should be exercised when using diphenhydramine hydrochloride, especially in older adults or individuals with pre-existing cognitive impairment.
Fall Risk: The sedative and anticholinergic effects of diphenhydramine hydrochloride can also increase the risk of falls, particularly in older adults. This risk is further elevated when diphenhydramine is combined with other medications that have similar effects on cognition and balance.
Other Considerations: Diphenhydramine hydrochloride may interact with other medications, including prescription drugs and over-the-counter products. It's essential to inform healthcare providers about all medications being taken to avoid potential interactions.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 2.3 | 0.3 | 6.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 1.9 | 0.8 | 1.37 |
| Allergies | 3.4 | 1.5 | 1.27 |
| Allergy to milk products | 1.2 | 1.3 | -0.08 |
| Alopecia (Hair Loss) | 0.1 | 0.1 | |
| Alzheimer's disease | 3.3 | 4.6 | -0.39 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2 | 0.7 | 1.86 |
| Ankylosing spondylitis | 2.4 | 0.9 | 1.67 |
| Anorexia Nervosa | 1.1 | 2.5 | -1.27 |
| Antiphospholipid syndrome (APS) | 1.2 | 1.2 | |
| Asthma | 3.3 | 2.1 | 0.57 |
| Atherosclerosis | 1 | 1.6 | -0.6 |
| Atrial fibrillation | 2.2 | 1.6 | 0.38 |
| Autism | 6 | 5.9 | 0.02 |
| Autoimmune Disease | 0.9 | 0.7 | 0.29 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.9 | 0.9 | |
| Bipolar Disorder | 1.8 | 1.1 | 0.64 |
| Brain Trauma | 0.3 | 0.8 | -1.67 |
| Breast Cancer | 0.3 | 0.3 | |
| Cancer (General) | 0.9 | 0.6 | 0.5 |
| Carcinoma | 2.6 | 1.1 | 1.36 |
| Celiac Disease | 2.8 | 1.9 | 0.47 |
| Cerebral Palsy | 1.3 | 1 | 0.3 |
| Chronic Fatigue Syndrome | 2.5 | 2.4 | 0.04 |
| Chronic Kidney Disease | 2.3 | 1.6 | 0.44 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 1.7 | -0.42 |
| Chronic Urticaria (Hives) | 1.6 | 0.7 | 1.29 |
| Coagulation / Micro clot triggering bacteria | 1.6 | 1 | 0.6 |
| Cognitive Function | 1.5 | 1.3 | 0.15 |
| Colorectal Cancer | 5.6 | 1.9 | 1.95 |
| Constipation | 1.8 | 0.7 | 1.57 |
| Coronary artery disease | 1.4 | 2 | -0.43 |
| COVID-19 | 5.9 | 5.4 | 0.09 |
| Crohn's Disease | 5.1 | 3.7 | 0.38 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.9 | 1 | -0.11 |
| d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
| deep vein thrombosis | 1.3 | 1.1 | 0.18 |
| Denture Wearers Oral Shifts | 0.4 | 0.4 | |
| Depression | 6.3 | 5.9 | 0.07 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.7 | 0.7 | 1.43 |
| Endometriosis | 2 | 1.7 | 0.18 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 2.7 | 1.7 | 0.59 |
| erectile dysfunction | 1.4 | 1.4 | |
| Fibromyalgia | 2.2 | 0.7 | 2.14 |
| Functional constipation / chronic idiopathic constipation | 4.1 | 2.2 | 0.86 |
| gallstone disease (gsd) | 2.1 | 1.1 | 0.91 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.4 | 1 | 0.4 |
| Generalized anxiety disorder | 2.4 | 1 | 1.4 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.9 | 0.4 | 1.25 |
| Graves' disease | 1 | 1.5 | -0.5 |
| Gulf War Syndrome | 0.6 | 0.9 | -0.5 |
| Halitosis | 1.2 | 0.3 | 3 |
| Hashimoto's thyroiditis | 2.3 | 1.1 | 1.09 |
| Heart Failure | 2.4 | 1.1 | 1.18 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.4 | 1.4 | |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.5 | 0.6 |
| hyperglycemia | 1.5 | 1.5 | 0 |
| Hyperlipidemia (High Blood Fats) | 0.2 | 0.2 | |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 3.2 | 2.3 | 0.39 |
| Hypothyroidism | 0.2 | 0.4 | -1 |
| Hypoxia | 2.4 | 2.4 | |
| IgA nephropathy (IgAN) | 1.6 | 1.6 | 0 |
| Inflammatory Bowel Disease | 5 | 5.4 | -0.08 |
| Insomnia | 1 | 2.8 | -1.8 |
| Intelligence | 1 | 1 | |
| Intracranial aneurysms | 1.1 | 1.1 | |
| Irritable Bowel Syndrome | 4 | 3.8 | 0.05 |
| ischemic stroke | 1.7 | 1.7 | 0 |
| Liver Cirrhosis | 4.7 | 3.4 | 0.38 |
| Long COVID | 4.7 | 3.5 | 0.34 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.6 | 0.6 | 0 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | |
| ME/CFS with IBS | 0.5 | 0.8 | -0.6 |
| ME/CFS without IBS | 1 | 0.3 | 2.33 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.8 | -1.67 |
| Metabolic Syndrome | 4.1 | 4.4 | -0.07 |
| Mood Disorders | 6.3 | 5 | 0.26 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.1 | 7 |
| Multiple Sclerosis | 4.2 | 3 | 0.4 |
| Multiple system atrophy (MSA) | 0.7 | 0.1 | 6 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 1.8 | -5 |
| Neuropathy (all types) | 0.9 | 1.6 | -0.78 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.6 | 2.9 | 0.24 |
| NonCeliac Gluten Sensitivity | 1.2 | 0.3 | 3 |
| Obesity | 5.3 | 4.7 | 0.13 |
| obsessive-compulsive disorder | 3.9 | 2.1 | 0.86 |
| Osteoarthritis | 2.1 | 0.8 | 1.63 |
| Osteoporosis | 2.2 | 1.2 | 0.83 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 5.5 | 4.6 | 0.2 |
| Polycystic ovary syndrome | 4.3 | 2 | 1.15 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | |
| Premenstrual dysphoric disorder | 0.1 | 0.4 | -3 |
| primary biliary cholangitis | 0.6 | 1 | -0.67 |
| Primary sclerosing cholangitis | 1.9 | 1.2 | 0.58 |
| Psoriasis | 1.6 | 2 | -0.25 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.1 | 2.5 | 0.24 |
| Rosacea | 0.3 | 0.7 | -1.33 |
| Schizophrenia | 3.9 | 2.4 | 0.63 |
| scoliosis | 0.3 | 0.3 | 0 |
| Sjögren syndrome | 2.1 | 1.3 | 0.62 |
| Sleep Apnea | 0.7 | 1.3 | -0.86 |
| Slow gastric motility / Gastroparesis | 0.8 | 0.8 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 1.6 | |
| Stress / posttraumatic stress disorder | 2.3 | 1.9 | 0.21 |
| Systemic Lupus Erythematosus | 3.3 | 1.3 | 1.54 |
| Tic Disorder | 1.2 | 1.2 | |
| Tourette syndrome | 0.5 | 0.3 | 0.67 |
| Type 1 Diabetes | 3.1 | 2.2 | 0.41 |
| Type 2 Diabetes | 5.1 | 4.4 | 0.16 |
| Ulcerative colitis | 4.4 | 3.4 | 0.29 |
| Unhealthy Ageing | 2.6 | 1.7 | 0.53 |
| Vitiligo | 1.5 | 0.9 | 0.67 |
